UY28586A1 - Formas de administración masticables, no comprimidas dosificadas individualmente - Google Patents

Formas de administración masticables, no comprimidas dosificadas individualmente

Info

Publication number
UY28586A1
UY28586A1 UY28586A UY28586A UY28586A1 UY 28586 A1 UY28586 A1 UY 28586A1 UY 28586 A UY28586 A UY 28586A UY 28586 A UY28586 A UY 28586A UY 28586 A1 UY28586 A1 UY 28586A1
Authority
UY
Uruguay
Prior art keywords
compressed
administration forms
individually dosed
masticable
fatty acids
Prior art date
Application number
UY28586A
Other languages
English (en)
Spanish (es)
Inventor
Fabregas Vidal Jose Luis
Masso Carbonell Antoni
Garcia Gonzalez Nuria
Guiro Coll Pere
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28586(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of UY28586A1 publication Critical patent/UY28586A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UY28586A 2003-11-10 2004-10-28 Formas de administración masticables, no comprimidas dosificadas individualmente UY28586A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302612A ES2235626B1 (es) 2003-11-10 2003-11-10 Formas de administracion masticables, no comprimidas dosificadas individualmente.

Publications (1)

Publication Number Publication Date
UY28586A1 true UY28586A1 (es) 2005-05-31

Family

ID=34610359

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28586A UY28586A1 (es) 2003-11-10 2004-10-28 Formas de administración masticables, no comprimidas dosificadas individualmente

Country Status (25)

Country Link
US (1) US20070134318A1 (enExample)
EP (1) EP1682097B1 (enExample)
JP (1) JP4879021B2 (enExample)
KR (1) KR20060116821A (enExample)
CN (1) CN1878542A (enExample)
AR (1) AR048050A1 (enExample)
AT (1) ATE492270T1 (enExample)
AU (1) AU2004290517B2 (enExample)
BR (1) BRPI0416215A (enExample)
CA (1) CA2548615A1 (enExample)
CO (1) CO5690531A2 (enExample)
DE (1) DE602004030706D1 (enExample)
EC (1) ECSP066553A (enExample)
ES (2) ES2235626B1 (enExample)
IL (1) IL175285A (enExample)
MY (1) MY143793A (enExample)
NO (1) NO20062723L (enExample)
NZ (1) NZ546375A (enExample)
PE (1) PE20050488A1 (enExample)
RU (1) RU2369379C2 (enExample)
TW (1) TW200526266A (enExample)
UA (1) UA90253C2 (enExample)
UY (1) UY28586A1 (enExample)
WO (2) WO2005048975A1 (enExample)
ZA (1) ZA200602416B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
AU2007288253B2 (en) 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
BRPI0719590A2 (pt) 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
EP2170282A4 (en) * 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2323735A1 (en) 2008-07-29 2011-05-25 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
CA2766107A1 (en) 2009-06-25 2010-12-29 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
EA021368B1 (ru) * 2011-06-21 2015-06-30 Общество С Ограниченной Ответственностью "Консорциум-Пик" Препарат кардиопротекторного действия
CN105911057B (zh) * 2016-06-22 2018-10-19 扬州一洋制药有限公司 一种铝镁加混悬液的质量控制方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
KR20220098746A (ko) 2019-11-08 2022-07-12 제논 파마슈티칼스 인크. 우울 장애 치료 방법
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
CN113425694A (zh) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 一种石斛生物碱口腔崩解片剂及其制备方法
US12053484B2 (en) 2021-10-29 2024-08-06 Medicated Chews, Llc Simethicone chewable composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645411A (en) * 1979-09-20 1981-04-25 Taiho Yakuhin Kogyo Kk Poultice
FR2515035A1 (fr) * 1981-10-26 1983-04-29 Rhone Poulenc Sante Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JPH0912463A (ja) * 1995-06-23 1997-01-14 Fujisawa Pharmaceut Co Ltd 口中咀嚼用製剤
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
CZ306277B6 (cs) * 2001-02-14 2016-11-09 Gw Pharma Limited Pumpičkou aktivovaná kapalná sprejová formulace
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
RU2197094C1 (ru) * 2001-12-26 2003-01-27 Ставрулов Игорь Анатольевич Жевательная резинка

Also Published As

Publication number Publication date
JP2007510690A (ja) 2007-04-26
US20070134318A1 (en) 2007-06-14
IL175285A (en) 2011-04-28
PE20050488A1 (es) 2005-08-24
NO20062723L (no) 2006-06-12
WO2005048974A3 (en) 2006-02-23
ES2235626B1 (es) 2006-11-01
UA90253C2 (ru) 2010-04-26
RU2369379C2 (ru) 2009-10-10
CA2548615A1 (en) 2005-06-02
MY143793A (en) 2011-07-15
CN1878542A (zh) 2006-12-13
AU2004290517A1 (en) 2005-06-02
ES2235626A1 (es) 2005-07-01
ZA200602416B (en) 2009-06-24
ECSP066553A (es) 2006-12-20
NZ546375A (en) 2009-11-27
TW200526266A (en) 2005-08-16
ATE492270T1 (de) 2011-01-15
ES2358332T3 (es) 2011-05-09
WO2005048974A2 (en) 2005-06-02
AR048050A1 (es) 2006-03-29
RU2006120087A (ru) 2007-12-27
WO2005048975A1 (en) 2005-06-02
JP4879021B2 (ja) 2012-02-15
CO5690531A2 (es) 2006-10-31
EP1682097B1 (en) 2010-12-22
BRPI0416215A (pt) 2006-12-26
KR20060116821A (ko) 2006-11-15
EP1682097A2 (en) 2006-07-26
IL175285A0 (en) 2006-09-05
DE602004030706D1 (de) 2011-02-03
AU2004290517B2 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
UY28586A1 (es) Formas de administración masticables, no comprimidas dosificadas individualmente
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
ES2529167T3 (es) Método para utilizar lípidos neutros para modificar la liberación in vivo desde liposomas multivesiculares
EA200300634A1 (ru) Фармацевтическая композиция, содержащая действующее вещество, диспергированное в матрице
AR117404A2 (es) Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
AR004483A1 (es) Compuestos para uso en terapia que comprenden un residuo de 1,3-propano diol como agente enlazante entre el residuo de ácido graso y un residuo bioactivo, usos de dichos compuestos y medicamentos , alimentos y formulaciones para el cuidado o tratamiento de la piel que comprenden a dichos compuestos
BR0014549A (pt) Artigo elástico
EA200101266A1 (ru) Новый препарат и форма для введения, включающие неустойчивое в кислой среде действующее вещество
AR033808A1 (es) Una composicion topica de anestesia local y los parches y los envases que la contienen
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
ES2182351T3 (es) Composicion farmaceutica en aerosol.
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
CA2518918A1 (en) Alpha-hydroxy acid ester drug delivery compositions and methods of use
AR068015A2 (es) Microgranulos de sulfato de morfina procedimiento para su preparacion y composicion que los contiene
CY1108285T1 (el) Σφαιροειδη, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις
PE20050923A1 (es) Composicion solida que comprende un sensibilizador de insulina, un secretagogo de insulina y un ester de acidos grasos
AR033861A1 (es) Sistema terapeutico transcutaneo con testosterona y procedimiento para su fabricacion
BRPI0418070A (pt) composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais
CO6260054A2 (es) Extruidos con enmascaramiento del sabor mejorado
FI935051A0 (fi) Lanolinderivat som penetrationfraemjande aemnen och anvaendning av dessa i preparat innehaollande laekemedel eller andra biologiskt aktiva substanser
DE602004014964D1 (de) Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel
MX2007006775A (es) Composiciones estables de fenofibrato con esteres de acido graso.
AR044113A1 (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
ATE345777T1 (de) Biologisch aktive zusammensetzung
ES2155048T1 (es) Composicion biologicamente activa.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150526